The role of 5-lipoxygenase products in preclinical models of asthma

Craig D. Wegner, Robert H. Gundel, William M. Abraham, Edward S. Schulman, Mark J. Kontny, Edward S. Lazer, Carol A. Homon, Anne G. Graham, Carol A. Torcellini, Cosmos C. Clarke, Paul Jager, Walter W. Wolyniec, L. Gordon Letts, Peter R. Farina

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: The action of 5-lipoxygenase on arachidonic acid generates potent inflammatory mediators that may contribute to the pathophysiology of asthma. Methods: Using the potent and selective 5-lipoxygenase inhibitor BI-L-239, we have examined the role of 5-lipoxygenase products in three animal models of asthma. Results: In vitro BI-L-239 inhibited 5-lipoxygenase product generation from human lung mast cells, alveolar macrophages, and peripheral blood leukocytes with a concentration that would provide 50% inhibition values of 28 to 340 nmol/L. A 36-fold selectivity for immunoreactive leukotriene C4 versus immunoreactive prostaglandin D2 inhibition was demonstrated in mast cells. In anesthetized cynomolgus monkeys, inhaled Bi-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced immunoreactive leukotriene C4 release (maximum, 73%; bronchoalveolar lavage [BAL], 20 minutes), late-phase bronchoconstriction (maximum, 41%; + 6 to 8 hours), and neutrophil infiltration (maximum, 63%; BAL, +8 hours). In conscious sheep, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced late-phase bronchoconstriction (maximum, 66%; + 6 to 8 hours) and increase in airway responsiveness (maximum, 82%; carbachol, + 24 hours). The acute bronchoconstriction was shortened, and neutrophil infiltration diminished (maximum, 61%; BAL, + 8 hours) in this model. Finally in conscious actively sensitized guinea pigs pretreated with pyrilamine and indomethacin, inhaled BI-L-239 attenuated acute bronchoconstriction (maximum, 80%; + 5 to 15 minutes), leukocyte infiltration (58%; BAL, + 3 days) and increase in airway responsiveness (100%; methacholine, + 3 days) induced by three alternate-day ovalbumin inhalations. Conclusions: In conclusion, results in these three animal models indicate that 5-lipoxygenase products may be major contributors to the bronchoconstriction (especially late phase), leukocyte infiltration, and airway hyperresponsiveness that characterize asthma.

Original languageEnglish
Pages (from-to)917-929
Number of pages13
JournalJournal of Allergy and Clinical Immunology
Volume91
Issue number4
StatePublished - Dec 1 1993
Externally publishedYes

Fingerprint

Arachidonate 5-Lipoxygenase
Bronchoconstriction
Bronchoalveolar Lavage
Asthma
Ascaris
Leukotriene C4
Leukocytes
Neutrophil Infiltration
Mast Cells
Animal Models
Pyrilamine
Prostaglandin D2
Lipoxygenase Inhibitors
Macaca fascicularis
Methacholine Chloride
Ovalbumin
Alveolar Macrophages
Carbachol
Indomethacin
Inhalation

Keywords

  • Airway hyperresponsiveness
  • Late-phase response
  • Leukocytes
  • Leukotrienes
  • Prostaglandins

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Wegner, C. D., Gundel, R. H., Abraham, W. M., Schulman, E. S., Kontny, M. J., Lazer, E. S., ... Farina, P. R. (1993). The role of 5-lipoxygenase products in preclinical models of asthma. Journal of Allergy and Clinical Immunology, 91(4), 917-929.

The role of 5-lipoxygenase products in preclinical models of asthma. / Wegner, Craig D.; Gundel, Robert H.; Abraham, William M.; Schulman, Edward S.; Kontny, Mark J.; Lazer, Edward S.; Homon, Carol A.; Graham, Anne G.; Torcellini, Carol A.; Clarke, Cosmos C.; Jager, Paul; Wolyniec, Walter W.; Letts, L. Gordon; Farina, Peter R.

In: Journal of Allergy and Clinical Immunology, Vol. 91, No. 4, 01.12.1993, p. 917-929.

Research output: Contribution to journalArticle

Wegner, CD, Gundel, RH, Abraham, WM, Schulman, ES, Kontny, MJ, Lazer, ES, Homon, CA, Graham, AG, Torcellini, CA, Clarke, CC, Jager, P, Wolyniec, WW, Letts, LG & Farina, PR 1993, 'The role of 5-lipoxygenase products in preclinical models of asthma', Journal of Allergy and Clinical Immunology, vol. 91, no. 4, pp. 917-929.
Wegner CD, Gundel RH, Abraham WM, Schulman ES, Kontny MJ, Lazer ES et al. The role of 5-lipoxygenase products in preclinical models of asthma. Journal of Allergy and Clinical Immunology. 1993 Dec 1;91(4):917-929.
Wegner, Craig D. ; Gundel, Robert H. ; Abraham, William M. ; Schulman, Edward S. ; Kontny, Mark J. ; Lazer, Edward S. ; Homon, Carol A. ; Graham, Anne G. ; Torcellini, Carol A. ; Clarke, Cosmos C. ; Jager, Paul ; Wolyniec, Walter W. ; Letts, L. Gordon ; Farina, Peter R. / The role of 5-lipoxygenase products in preclinical models of asthma. In: Journal of Allergy and Clinical Immunology. 1993 ; Vol. 91, No. 4. pp. 917-929.
@article{be7a0d01d85b4506a38959bd84fbd2b0,
title = "The role of 5-lipoxygenase products in preclinical models of asthma",
abstract = "Background: The action of 5-lipoxygenase on arachidonic acid generates potent inflammatory mediators that may contribute to the pathophysiology of asthma. Methods: Using the potent and selective 5-lipoxygenase inhibitor BI-L-239, we have examined the role of 5-lipoxygenase products in three animal models of asthma. Results: In vitro BI-L-239 inhibited 5-lipoxygenase product generation from human lung mast cells, alveolar macrophages, and peripheral blood leukocytes with a concentration that would provide 50{\%} inhibition values of 28 to 340 nmol/L. A 36-fold selectivity for immunoreactive leukotriene C4 versus immunoreactive prostaglandin D2 inhibition was demonstrated in mast cells. In anesthetized cynomolgus monkeys, inhaled Bi-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced immunoreactive leukotriene C4 release (maximum, 73{\%}; bronchoalveolar lavage [BAL], 20 minutes), late-phase bronchoconstriction (maximum, 41{\%}; + 6 to 8 hours), and neutrophil infiltration (maximum, 63{\%}; BAL, +8 hours). In conscious sheep, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced late-phase bronchoconstriction (maximum, 66{\%}; + 6 to 8 hours) and increase in airway responsiveness (maximum, 82{\%}; carbachol, + 24 hours). The acute bronchoconstriction was shortened, and neutrophil infiltration diminished (maximum, 61{\%}; BAL, + 8 hours) in this model. Finally in conscious actively sensitized guinea pigs pretreated with pyrilamine and indomethacin, inhaled BI-L-239 attenuated acute bronchoconstriction (maximum, 80{\%}; + 5 to 15 minutes), leukocyte infiltration (58{\%}; BAL, + 3 days) and increase in airway responsiveness (100{\%}; methacholine, + 3 days) induced by three alternate-day ovalbumin inhalations. Conclusions: In conclusion, results in these three animal models indicate that 5-lipoxygenase products may be major contributors to the bronchoconstriction (especially late phase), leukocyte infiltration, and airway hyperresponsiveness that characterize asthma.",
keywords = "Airway hyperresponsiveness, Late-phase response, Leukocytes, Leukotrienes, Prostaglandins",
author = "Wegner, {Craig D.} and Gundel, {Robert H.} and Abraham, {William M.} and Schulman, {Edward S.} and Kontny, {Mark J.} and Lazer, {Edward S.} and Homon, {Carol A.} and Graham, {Anne G.} and Torcellini, {Carol A.} and Clarke, {Cosmos C.} and Paul Jager and Wolyniec, {Walter W.} and Letts, {L. Gordon} and Farina, {Peter R.}",
year = "1993",
month = "12",
day = "1",
language = "English",
volume = "91",
pages = "917--929",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - The role of 5-lipoxygenase products in preclinical models of asthma

AU - Wegner, Craig D.

AU - Gundel, Robert H.

AU - Abraham, William M.

AU - Schulman, Edward S.

AU - Kontny, Mark J.

AU - Lazer, Edward S.

AU - Homon, Carol A.

AU - Graham, Anne G.

AU - Torcellini, Carol A.

AU - Clarke, Cosmos C.

AU - Jager, Paul

AU - Wolyniec, Walter W.

AU - Letts, L. Gordon

AU - Farina, Peter R.

PY - 1993/12/1

Y1 - 1993/12/1

N2 - Background: The action of 5-lipoxygenase on arachidonic acid generates potent inflammatory mediators that may contribute to the pathophysiology of asthma. Methods: Using the potent and selective 5-lipoxygenase inhibitor BI-L-239, we have examined the role of 5-lipoxygenase products in three animal models of asthma. Results: In vitro BI-L-239 inhibited 5-lipoxygenase product generation from human lung mast cells, alveolar macrophages, and peripheral blood leukocytes with a concentration that would provide 50% inhibition values of 28 to 340 nmol/L. A 36-fold selectivity for immunoreactive leukotriene C4 versus immunoreactive prostaglandin D2 inhibition was demonstrated in mast cells. In anesthetized cynomolgus monkeys, inhaled Bi-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced immunoreactive leukotriene C4 release (maximum, 73%; bronchoalveolar lavage [BAL], 20 minutes), late-phase bronchoconstriction (maximum, 41%; + 6 to 8 hours), and neutrophil infiltration (maximum, 63%; BAL, +8 hours). In conscious sheep, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced late-phase bronchoconstriction (maximum, 66%; + 6 to 8 hours) and increase in airway responsiveness (maximum, 82%; carbachol, + 24 hours). The acute bronchoconstriction was shortened, and neutrophil infiltration diminished (maximum, 61%; BAL, + 8 hours) in this model. Finally in conscious actively sensitized guinea pigs pretreated with pyrilamine and indomethacin, inhaled BI-L-239 attenuated acute bronchoconstriction (maximum, 80%; + 5 to 15 minutes), leukocyte infiltration (58%; BAL, + 3 days) and increase in airway responsiveness (100%; methacholine, + 3 days) induced by three alternate-day ovalbumin inhalations. Conclusions: In conclusion, results in these three animal models indicate that 5-lipoxygenase products may be major contributors to the bronchoconstriction (especially late phase), leukocyte infiltration, and airway hyperresponsiveness that characterize asthma.

AB - Background: The action of 5-lipoxygenase on arachidonic acid generates potent inflammatory mediators that may contribute to the pathophysiology of asthma. Methods: Using the potent and selective 5-lipoxygenase inhibitor BI-L-239, we have examined the role of 5-lipoxygenase products in three animal models of asthma. Results: In vitro BI-L-239 inhibited 5-lipoxygenase product generation from human lung mast cells, alveolar macrophages, and peripheral blood leukocytes with a concentration that would provide 50% inhibition values of 28 to 340 nmol/L. A 36-fold selectivity for immunoreactive leukotriene C4 versus immunoreactive prostaglandin D2 inhibition was demonstrated in mast cells. In anesthetized cynomolgus monkeys, inhaled Bi-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced immunoreactive leukotriene C4 release (maximum, 73%; bronchoalveolar lavage [BAL], 20 minutes), late-phase bronchoconstriction (maximum, 41%; + 6 to 8 hours), and neutrophil infiltration (maximum, 63%; BAL, +8 hours). In conscious sheep, inhaled BI-L-239 provided dose-dependent inhibition of the inhaled Ascaris-induced late-phase bronchoconstriction (maximum, 66%; + 6 to 8 hours) and increase in airway responsiveness (maximum, 82%; carbachol, + 24 hours). The acute bronchoconstriction was shortened, and neutrophil infiltration diminished (maximum, 61%; BAL, + 8 hours) in this model. Finally in conscious actively sensitized guinea pigs pretreated with pyrilamine and indomethacin, inhaled BI-L-239 attenuated acute bronchoconstriction (maximum, 80%; + 5 to 15 minutes), leukocyte infiltration (58%; BAL, + 3 days) and increase in airway responsiveness (100%; methacholine, + 3 days) induced by three alternate-day ovalbumin inhalations. Conclusions: In conclusion, results in these three animal models indicate that 5-lipoxygenase products may be major contributors to the bronchoconstriction (especially late phase), leukocyte infiltration, and airway hyperresponsiveness that characterize asthma.

KW - Airway hyperresponsiveness

KW - Late-phase response

KW - Leukocytes

KW - Leukotrienes

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0027477589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027477589&partnerID=8YFLogxK

M3 - Article

C2 - 8473681

AN - SCOPUS:0027477589

VL - 91

SP - 917

EP - 929

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -